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Iron metabolism and homeostasis are dependent on the proper 
regulation of hepcidin, a small antimicrobial peptide expressed 
in the liver that has only recently been cloned and characterized 
(1). Genetic studies in mice lacking or overexpressing hepcidin 
suggest that this peptide inhibits both iron absorption in the 
small intestine and the release of recycled iron from macrophages 
(2, 3). To limit iron export, hepcidin blocks ferroportin, the sole 
known iron exporter, by binding to it and causing its internaliza-
tion and degradation (1). Hepcidin upregulation in response to 
chronic inflammatory stimuli (e.g., cancer, infection, autoimmu-
nity) leads to the anemia of chronic disease (4–7), while hepcidin 
downregulation is associated with the iron overload disorder of 
hemochromatosis (8–11).
Given the links among oxygen transport, erythropoiesis, and iron 
metabolism, there are potential associations between the physiol-
ogy of hypoxic response and the control of iron availability. To 
gain insight into potential hypoxia-dependent molecular mecha-
nisms that might control hepcidin expression in iron homeostasis, 
we examined transcriptional control of the hypoxic response in 
the liver by the hypoxia-inducible transcription factors (HIFs), key 
elements in the response to hypoxia (12). We hypothesized that 
this pathway could play a role in hepcidin regulation because: (a) 
iron deprivation and hypoferric anemia lead to poor tissue oxy-
genation; and (b) HIF levels are partially regulated by the tumor 
suppressor protein von Hippel–Lindau (VHL). The VHL protein 
regulates turnover of components of the HIF transcription factors 
through a process that requires molecular iron.
HIF is a heterodimer whose expression is regulated posttrans-
lationally. Three regulatory HIF subunits have been cloned and 
named HIF-1α, HIF-2α (13–15), and HIF-3α (16). In the presence 
of oxygen, the regulatory subunits are modified by iron-depen-
dent prolyl hydroxylases (PHDs) and are then degraded through 
the ubiquitin/proteasome pathway via its interaction with VHL. 
Under hypoxia or following iron chelation, PHD activity is inhibit-
ed. The regulatory subunit then accumulates and translocates into 
the nucleus, where it binds to aryl hydrocarbon receptor nuclear 
translocator/HIF-1β (ARNT/HIF-1β), which is constitutively 
expressed. The heterodimeric HIF binds to the hypoxia-response 
elements (HREs) of target gene regulatory sequences, resulting in 
the transcription of genes implicated in the control of metabo-
lism and angiogenesis, as well as apoptosis and cellular stress (12). 
Erythropoietin (EPO) is one of these direct target genes.
In this study, we establish HIF as an essential link between iron 
fluctuation and hepcidin regulation. The fact that hepcidin, ferro-
portin, and EPO under the control of VHL/HIF pathway allows a 
coordinated response for controlling iron metabolism and oxygen 
transport, regulating the processes that provide iron for physiologic 
processes such as erythropoiesis. These data provide what we believe 
to be the first molecular evidence for a coordination between the 
process of iron uptake and hypoxic response.
Results
HIF-1α is stabilized in the liver of iron-starved mice. Mutant mice with 
iron-deficiency anemia or rats fed an iron-deficient diet exhibit 
lower hepatic hepcidin expression than control animals (6, 17). 
Studies in patients with iron-deficiency anemia have also demon-
strated significantly reduced hepcidin levels relative to those of 
healthy subjects (18).
We observed that iron starvation of mice of the inbred C57BL/6 
strain resulted in a strong decrease in hepatic hepcidin mRNA 
expression compared with that in control mice fed a normal diet 
(Figure 1A). Mice in this same study had a clear increase in HIF-1α 
levels in the liver in response to the iron deficiency (Figure 1B). 
This demonstrates that HIF-1α expression in the liver is influ-
enced by dietary iron depletion.
Decreased regulation of hepcidin by nutritional iron when HIF-1α 
is deleted in hepatocytes. HIF-1α was specifically inactivated in 
hepatocytes by crossing C57BL/6 backcrossed HIF-1αflox/flox mice 
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with Albumin-Cre C57BL/6 transgenic mice. Deletion efficiency 
in total liver was approximately 70% as determined by quantita-
tive PCR (data not shown). This indicates a very high rate of 
hepatocyte deletion, since it is estimated that other cell types, 
such as endothelial cells and Kupffer cells, make up approxi-
mately 30% of the cells in the liver (19). Under a standard iron-
rich laboratory diet, HIF-1α expression was not detectable in the 
liver (Figure 1B); and no significant differences in hepatic hep-
cidin expression were observed between WT and Albumin-Cre/ 
HIF-1αflox/flox mice (Figure 1C).
After 20 days of feeding with an iron-deficient diet, Albumin-Cre/ 
HIF-1αflox/flox mice expressed 10-fold more hepcidin than WT litter-
mates (Figure 1C), indicating that deletion of HIF-1α affects the 
physiological mechanisms governing hepcidin downregulation 
during nutritional iron deficiency. However, we found that elimi-
nation of HIF-1α alone is insufficient to fully compensate for the 
hepcidin reduction caused by an iron-deficient diet (Figure 1C), 
suggesting that other factors also contribute to the observed hep-
cidin downregulation.
Deletion of VHL in hepatocytes results in polycythemia and iron defi-
ciency. The VHL pathway that controls HIF-1α levels also regu-
lates HIF-2α, which in turn is thought to have unique roles in 
regulating liver tumorigenesis and EPO expression (20). The VHL 
tumor suppressor regulates the oxygen-sensitive turnover of both 
HIF-1α and HIF-2α transcription factors. To investigate the effect 
of altering the stability of both factors in vivo, we deleted VHL in 
the liver by crossing C57BL/6 VHLflox/flox mice with Albumin-Cre 
C57BL/6 transgenic mice.
Growth deficiency, polycythemia, and reduced survival occur 
when VHL is deleted in the liver in a mixed inbred strain genet-
ic background (BALB/c, 129SvJ, and C57BL/6) (21). In the pure 
C57BL/6 background, mice homozygous for the VHL mutation 
(Albumin-Cre/VHLflox/flox) in the liver demonstrated alopecia and 
grew to only half the weight of their WT littermates (Figure 2A), 
dying between 5 and 7 weeks of age with severe hepatomegaly and 
splenomegaly (Figure 2B). VHL deletion efficiency in total liver 
was approximately 50% as determined by quantitative PCR evalu-
ation of genomic DNA (data not shown).
The livers of Albumin-Cre/VHLflox/flox mice exhibited steatosis 
(pathologic fat accumulation), with inflammatory cell infiltration 
as well as foci of necrosis due to fibrin clots (Figure 2B); however, 
no fibrotic changes were noted. Albumin levels indicative of normal 
hepatic synthetic function were observed (data not shown). Serum 
levels of the HIF target gene 
EPO were increased, reflecting 
the strong upregulation of EPO 
mRNA in the liver of Albumin-
Cre/VHLflox/flox compared with 
WT mice (Figure 2C).
Increased EPO levels are 
consistent with the increased 
erythrocytosis and elevated 
hematocrit observed in the 
Albumin-Cre/VHLflox/flox mice 
(Figure 2C). Although total 
hemoglobin levels were elevated 
(Figure 2C), mean cell hemo-
globin (MCH) was decreased 
in Albumin-Cre/VHLflox/flox mice 
compared with WT mice (Fig-
ure 2D). This result indicates a relative iron deficiency in the ani-
mals. The observation was corroborated by the hypochromia, poi-
kilocytosis, and microcytosis observed in blood smears from the 
Albumin-Cre/VHLflox/flox mice (Figure 2D).
Total iron (Figure 2E) and ferritin (Figure 2F) levels in the livers 
of Albumin-Cre/VHLflox/flox mice were also greatly reduced relative to 
those of WT mice. The spleen, another reservoir of iron, was also 
strongly iron deficient according to Perls Prussian blue staining, 
as shown in Figure 2G.
The phenotype of the Albumin-Cre/VHLflox/flox mice is similar in 
some regards to that of humans with Chuvash polycythemia, in 
which a homozygous mutation (598C→T) in the VHL gene leads 
to elevated normoxic levels of HIF-1, serum EPO, and hemoglobin 
and premature mortality related to cerebral vascular events and 
peripheral thrombosis (22, 23).
HIF-1 binds to the promoter of hepcidin in vivo and reduces its 
expression in the liver. We detected 2 candidate consensus HREs 
([A/G]CGTG) in the murine hepcidin promoter (24) (Figure 3A). 
We performed a chromatin IP (ChIP) assay on liver tissues 
extracted from WT and Albumin-Cre/VHLflox/flox mice. Primers 
flanking HIF-1α consensus binding sites specifically amplified 
DNA sequences immunoprecipitated by an HIF-1α antibody, 
indicating that HIF-1α is able to bind the murine hepcidin pro-
moter in vivo (Figure 3A), which supports the assumption of 
direct regulation of hepcidin by HIF-1.
Examining the human hepcidin promoter sequence, we detect-
ed 3 candidate consensus HREs. We performed a ChIP on human 
HEK293 cells stimulated with the iron chelator desferrioxamine 
mesylate (DFO) in order to stabilize HIF-1α. In these condi-
tions, primers flanking HIF-1α consensus binding sites specifi-
cally amplified DNA sequence immunoprecipitated by HIF-1α 
antibody, showing that HIF-1α is able to bind the hepcidin pro-
moter in human cells as well as mouse tissues (Figure 3B). We 
next examined whether the putative classical and conserved HRE 
(first of 2 HREs arranged as inverted repeats) in the human hep-
cidin promoter was important for the iron-dependent regulation 
of hepcidin expression. We cloned the promoter region of the 
human hepcidin encompassing the HREs into a luciferase report-
er construct. The HIF agonist DFO strongly inhibited luciferase 
activity of this plasmid (pGL3-Hepc/HRE) (Figure 3C), suggest-
ing that HIF binding to the hepcidin promoter suppresses hep-
cidin gene transcription. To verify that the putative Hepc/HRE 
located at –582 bp is the target of repression by HIF, we intro-
Figure 1
Iron deficiency downregulates hepcidin in an HIF-1–dependent fashion. (A) Hepcidin mRNA level in livers 
of WT mice under regular or low-iron diet (3 weeks), determined by real-time RT-PCR. Results, normalized 
to 18S ribosomal RNA expression, are expressed as mean ± SD (n = 5 in each group). (B) HIF-1 expression 
in liver extracts of iron-starved WT mice by Western blotting. (C) Hepcidin mRNA expression in livers of WT 
and Albumin-Cre/HIF-1αflox/flox (HIF-1–/–) iron-starved mice by real-time RT-PCR (n = 8).
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duced a point mutation (5′-CAA-TG-3′ instead of 5′-CACGTG-3′) 
into this sequence (Figure 3D). The activity of the correspond-
ing plasmid that bears the mutation (pGL3-Hepc/mutHRE) was 
increased compared with that of the pGL3-Hepc/HRE plasmid. 
These results demonstrate that the sequence covering the con-
sensus HIF-1 binding site is involved in the downregulation of 
hepcidin gene transcription by HIF.
We next assessed whether the increased amounts of HIF-1α in the 
liver, and its binding to the hepcidin promoter regulate the hepci-
din gene in murine tissues. As shown in Figure 3E, Hepc1 mRNA 
levels measured in the liver of Albumin-Cre/VHLflox/flox mice were 
markedly decreased compared with those of WT littermates. Anal-
ysis of protein levels confirmed that levels of the hepcidin peptide 
were also lower in Albumin-Cre/VHLflox/flox mice (Figure 3E).
Downregulation of Hepc1 mRNA in Albumin-Cre/VHLflox/flox 
mice was eliminated, i.e., transcript levels returned to normal 
values, in Albumin-Cre/VHLflox/flox/ARNTflox/flox double mutant 
(double-knockout) mice (Figure 3F). These mice have a hepatic 
deletion of both the VHL gene, whose absence causes increased 
HIF activity, and the ARNT gene, which is required for dimeriza-
tion and thus activation of HIF-mediated transcription. The res-
toration of hepcidin to normal levels in the livers of these double 
Figure 2
Albumin-Cre/VHLflox/flox mice develop erythrocytosis and iron deficiency. (A) WT and Albumin-Cre/VHLflox/flox (VHL–/–) mice (4 weeks old). Right: 
Spleen and liver weights of 3- to 4-week-old WT and Albumin-Cre/VHLflox/flox mice (n = 8 in each group). (B) H&E stainings of liver sections from 
WT and Albumin-Cre/VHLflox/flox mice. Solid arrow indicates steatosis, dashed arrow inflammatory cell infiltrate. (C) EPO mRNA expression in 
kidney and liver of WT (black bars) and Albumin-Cre/VHLflox/flox (gray bars) mice by real-time RT-PCR (n = 8). EPO, rbc, hematocrit, and hemoglo-
bin levels in blood or serum from 5-week-old mice. n = 8 in each group. (D) Peripheral blood smears from WT and Albumin-Cre/VHLflox/flox mice. 
Solid arrow indicates hypochromasia, dashed arrow anisocytosis. Right: mean corpuscular hemoglobin (MCH) of WT and Albumin-Cre/VHLflox/flox 
mice. Original magnification, ×200. (E) Quantification of liver iron level in WT and Albumin-Cre/VHLflox/flox mice using the method of Torrance et 
al. (33) (n = 5 in each group). (F) Western blot analysis of ferritin in liver extracts from WT and Albumin-Cre/VHLflox/flox mice. (G) Iron staining of 
splenic sections by Perls Prussian blue. Original magnification, ×200.
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mutants demonstrates that hepcidin downregulation in Albumin-
Cre/VHLflox/flox mice is specifically due to the stabilization of HIF 
transcription factors (i.e., HIF-1α and HIF-2α) and not to other 
functions of the VHL gene.
As Albumin-Cre/VHLflox/flox mice exhibit hepatic inflammation 
and steatosis (21) (Figure 2C), we examined levels of the proin-
flammatory cytokine IL-6, which is known to stimulate hepcidin 
expression and may contribute to the anemia of chronic inflam-
mation (5). Significantly elevated IL-6 and IL-1 levels were found in 
the Albumin-Cre/VHLflox/flox mice (Figure 3G), although this change 
did not prevent the decreased hepcidin expression described above. 
These findings indicate that IL-6– or IL-1–mediated stimulation 
of hepcidin expression is subordinate to the suppression caused by 
increased HIF transcriptional activity.
Upregulation of ferroportin in Albumin-Cre/VHLflox/flox mice. It 
has recently been shown ex vivo that hepcidin binds ferro-
portin, the only known iron exporter, thereby trapping iron 
within enterocytes and macrophages (1). By immunochemis-
try, we found significant increases in ferroportin expression 
in brush border enterocytes of the duodenum of Albumin-Cre/
VHLflox/flox mice compared with WT mice (Figure 4A). A like-
ly explanation for this finding is the loss of hepcidin-medi-
ated ferroportin degradation in the Albumin-Cre/VHLflox/flox 
mice. Analysis of liver sections from Albumin-Cre/VHLflox/flox 
mice revealed a marked increase in ferroportin in the Kupffer cells 
of the liver, again, a likely consequence of the decreased hepcidin 
levels seen in these animals. Interestingly, this was also seen in the 
Albumin-Cre/VHLflox/flox hepatocytes (Figure 4A).
Western blot analysis confirmed the increase in ferroportin 
expression in whole liver extracts from Albumin-Cre/VHLflox/flox mice 
relative to WT mice (Figure 4B). Increased ferroportin levels in the 
hepatocytes may in part reflect a small but statistically signifi-
cant increase in hepatic ferroportin mRNA expression detected in 
Albumin-Cre/VHLflox/flox mice (Figure 4C). While ferroportin expres-
sion in the duodenum could result from the decrease in systemic 
hepcidin expression or from the systemic iron deficiency itself (25), 
Figure 3
Binding of HIF-1 to the promoter of hepcidin and downregulation of hepcidin in Albumin-Cre/VHLflox/flox. (A) Sequence of murine (C57BL/6) 
hepcidin promoter; HREs are in bold; arrows indicate primers selected for ChIP. ChIP assay in vivo on liver extracts of WT and Albumin-Cre/
VHLflox/flox mice. (B) DFO (150 μM) induces binding of HIF-1 as shown by ChIP assay. (C) Luciferase-reporter constructs under the control of 
the regulatory region of the human hepcidin gene. HEK293 cells transiently transfected with pGL3 basic or pGL3-Hepc/HRE vector. (D) The 
“native” (CCACGTG) and mutated (CAA-TG) HREs (indicated by an X) are shown. HEK293 cells were transiently transfected with pGL3 basic, 
pGL3-Hepc/HRE, or pGL3-Hepc/mutHRE. (E) Hepcidin mRNA expression in livers of WT and Albumin-Cre/VHLflox/flox by real-time RT-PCR 
(n = 8). HIF-1 and hepcidin expression in liver extracts of WT and Albumin-Cre/VHLflox/flox mice. (F) Hepcidin mRNA expression in livers of WT, 
Albumin-Cre/VHLflox/flox, and Albumin-Cre/VHLflox/flox/ARNTflox/flox (VHL–/–ANRT–/–) mice (n = 4). (G) IL-6 and IL-1β mRNA levels in livers of WT 
and Albumin-Cre/VHLflox/flox mice.
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expression of ferroportin in the hepatocyte may reflect a direct tis-
sue-autonomous effect of VHL-deficient cells. Indeed, as previous-
ly reported, iron export in hepatocytes is likely independent of the 
posttranslational regulation of ferroportin by hepcidin (26, 27).
Discussion
Hepcidin is suppressed by both anemia and hypoxia (7). Cellu-
lar oxygen sensing and hypoxia-induced transcription are largely 
mediated by the HIFs. The stabilization of HIF-1 by iron chelators 
has been well established in vitro. However, our demonstration of 
the in vivo induction of HIF-1 by iron deficiency, and the asso-
ciated downregulation of hepcidin when HIF levels are elevated, 
suggests that HIF may be one of the missing links between iron 
homeostasis and hepcidin regulation. The ability of HIF-1α to 
bind to and negatively transactivate the hepcidin promoter sug-
gests a direct repressor effect. HIF-1α has already been reported to 
repress the transcriptional activity of genes such as alpha-fetopro-
tein (AFP) (28) and carbamoyl-phosphate synthetase 2, aspartate 
transcarbamylase, and dihydroorotase (CAD) (29).
Our data show that elimination of HIF-1 alone in adult mice 
is insufficient to fully compensate for the hepcidin reduction 
induced by iron depletion. The striking downregulation of hepci-
din observed in Albumin-Cre/VHLflox/flox mice, in which both HIF-1 
and HIF-2 are stabilized, may suggest a role for HIF-2. HIF-1 
may influence embryonic, developmental hepcidin regulation; as 
Yoon et al. demonstrated, a decrease in TfR in Hif-1a–/– embryos 
contributes to defects in iron metabolism and consequently an 
alteration of hepcidin levels (30).
We propose that the VHL/HIF axis serves a central role in 
coupling iron sensing to iron regulation. In this model, ane-
mia causes decreased tissue oxygenation, which in turn leads 
to decreased PHD activity and thus decreased VHL-mediated 
degradation of HIF-α factors. Increased HIF-α activity causes 
suppression of hepcidin, increased ferroportin levels, and 
increased serum iron availability; these in turn allow increased 
erythropoiesis to be coupled to increased EPO expression.
In support of a role for the HIF axis in regulating this process, we 
have shown that hepatic deletion of the VHL gene causes decreased 
hepcidin levels and increased ferroportin expression. Interestingly, 
in the face of dramatically increased EPO levels and polycythemia, 
the VHL-deficient animals exhibited microcytosis and low MCH 
reminiscent of iron-deficiency. This finding suggests a form of 
“iron-EPO kinetic imbalance,” where the robust proliferation of 
erythroid precursors creates a demand that outstrips the capacity 
of the iron delivery system (31). Our model also suggests that inhi-
bition of VHL or PHD activity could represent a novel approach 
for treatment of anemia of chronic inflammation, since stabiliza-
tion of HIF prevents hepcidin activation even under the strong 
stimulus of the proinflammatory cytokine IL-6.
It has been proposed that iron balance is conceptually coupled 
to intestinal iron absorption by 2 mechanisms, the “stores reg-
ulator” and the “erythroid regulator,” which can be fully char-
acterized only in physiological terms (32). Our results indicate 
the VHL/HIF axis concomitantly serves both the stores and ery-
throid regulator pathways, through its responsiveness to oxygen 
and iron levels and its function as a regulator of hepcidin, fer-
roportin, and EPO production.
Methods
Animals. All procedures involving animals were approved by the UCSD 
Animal Care Committee, which serves to ensure that all federal guide-
lines concerning animal experimentation are met. Hepatocyte-spe-
cific inactivation of HIF-1α and VHL was achieved by cross-breeding 
Albumin-Cre transgenic mice (The Jackson Laboratory) with VHLflox/flox 
mice (backcrossed in a pure C57BL/6 genetic background). In all experi-
ments, littermates from the same breeding pair were used as controls. 
Albumin-Cre/VHLflox/flox and Albumin-Cre/VHLflox/flox/ARNTflox/flox mice used 
in the experiments shown in Figure 3C are in a mixed BALB/c, 129SvJ, and 
C57BL/6 background. Mice were maintained on a standard rodent diet 
(formula LM-458, 7912; Harlan Teklad) containing 284 mg iron/kg. In cer-
tain experiments, mice were fed a low-iron (3–6 mg/kg food) diet (Formula 
TD 80396; Harlan Teklad) for 3 weeks.
Hematological analysis. Blood was obtained by retro-orbital bleeding and 
collected in EDTA-K2 tubes (CapiJect T-MLH; TERUMO). Blood cell 
counts and erythrocyte parameters were determined using a MAXM Coul-
ter (Beckman Coulter) automatic analyzer.
Immunohistochemistry. Tissues were fixed in 10% formalin sec-
tioned in paraffin, then subjected to microwave antigen retrieval and 
immunohistochemistry (Vector Blue Alkaline Phosphatase Kit; Vector Lab-
oratories) with primary antibodies against ferroportin (Alpha Diagnostic 
International) at 1:200. Iron detection was performed with Perls Prussian 
blue and nuclear red counter stain.
Figure 4
Upregulation of ferroportin in Albumin-Cre/VHLflox/flox mice. (A) 
Immunostaining for ferroportin in duodenum and liver sections from 
WT and Albumin-Cre/VHLflox/flox mice. Solid arrow indicates a hepa-
tocyte, dashed arrow a Kupffer cell. (B) Ferroportin expression in 
liver extracts of WT and Albumin-Cre/VHLflox/flox mice. (C) Ferroportin 
mRNA levels in livers of WT and Albumin-Cre/VHLflox/flox mice. Results 
are expressed as mean ± SD (n ≥ 4 in each group); statistical analysis 
was done using Student’s t test (unpaired, 2 tailed).
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Iron quantification. Tissue iron was quantified colorimetrically by a 
modification of the method of Torrance et al. (33). Fifty- to 100-mg liver 
extracts were digested overnight in 100 μl 3 M HCl/10% trichloroace-
tic acid at 65°C, followed by the addition of 200 μl chromogen (0.01% 
bathophenanthroline sulfonate, 0.1% thioglycolic acid, and 4 M sodium 
acetate). For a standard curve, serial dilutions of a ferric iron standard 
(Sigma-Aldrich) were used. Color was allowed to develop for 15 minutes 
and measured at 535 nm.
RT and real-time quantitative PCR. First-strand synthesis was obtained 
from 1 μg of total RNA isolated with TRI reagent (Molecular Research 
Center Inc.) by the SuperScript system (Invitrogen) employing random 
primers. For real-time PCR analyses, cDNAs were diluted to a final 
concentration of 10 ng/μl and amplified in a SYBR Green TaqMan 
Universal Master Mix (Applied Biosystems). Fifty nanograms cDNA 
was used as template to determine the relative amount of mRNA by 
real-time PCR in triplicate (ABI Prism 7700 sequence detection sys-
tem; Applied Biosystems), using specific primers with the following 
sequences: hepcidin forward, 5′-TGTCTCCTGCTTCTCCTCCT-3′; 
hepcidin reverse, 5′-CTCTGTAGTCTGTCTCATCTGTTG-3′; ferro-
portin forward, 5′-CTACCATTAGAAGGATTGACCAGCTA-3′; fer-
roportin reverse, 5′-ACTGGAGAACCAAATGTCATAATCTG-3′; EPO 
forward, 5′-AATGGAGGTGGAAGAACAGGCCAT-3′; EPO reverse, 
5′-CGAAGCAGTGAAGTGAGGCTACGTA-3′; β-actin forward, 5′-
AGGCCCAGAGCAAGAGAGG-3′; β-actin reverse, 5′-TACATGGCT-
GGGGTGTTGAA-3′.
ChIP assay. For the in vivo ChIP assay, approximately 130 mg of livers 
from WT and VHL–/– mice were extracted and submitted to the protocol 
developed by Farnham’s laboratory and described at http://genomecenter.
ucdavis.edu/farnham/farnham/protocols/tissues.html.
Primers flanking the putative HREs within the murine Black6 Hepc pro-
moter were: –2366-mHEPC-F, 5′-CCATCACTTATAGTGGGCTC-3′, and 
–1915-mHEPC-R, 5′-GCCATTGTCACACAGCTACA-3′.
Western blot studies. Livers were harvested, ground in a mortar, and washed 
with PBS and proteins extracted with RIPA buffer. Twenty micrograms of 
total (for ferritin and ferroportin) or nuclear extracts (for hepcidin and 
HIF) were loaded on a 10% (ferritin and ferroportin), 12% (hepcidin), or 7% 
(HIF) gels, and Western blot analysis was performed using standard meth-
odologies. Primary antibodies were rabbit anti-mouse Hepcidin (Alpha 
Diagnostic International), rabbit anti–HIF-1α (Novus Biologicals), rabbit 
anti-ferroportin (Alpha Diagnostic International), and rabbit anti–ferritin 
heavy chain (Abcam) at a concentration of 1:1,000.
Transient transfection and luciferase assay. The hepcidin promoter lucifer-
ase reporter plasmid (pGL3-HRE) was constructed by cloning a PCR frag-
ment of the human hepcidin upstream region (–762 bp to –20 bp) into 
a pGL3 vector (Promega) by conventional cloning procedures to yield 
pGL3-Hepc/HRE. A mutation of the putative HRE, in which the CG in 
the CACGTG motif was replaced by an A, was generated by site-directed 
mutagenesis using the QuikChange Site-Directed Mutagenesis kit (Strat-
agene) as indicated by the manufacturer. The point mutation in the cor-
responding plasmid pGL3-Hepc/mutHRE was verified by sequencing. 
HEK293 cells were transfected by Lipofectamine 2000 (Invitrogen) with 
2 μg of pGL3, pGL3-Hepc/HRE, or pGL3-Hepc/mutHRE, according to the 
manufacturer’s protocol. The following day, cells were incubated with 
DFO at 150 μM for 18 hours. Cells were then washed with PBS and lysed 
with the reporter gene assay lysis buffer (Roche), and luciferase assay was 
performed using the Bright-Glo Luciferase Assay kit (Promega).
Statistics. All values in the figures are expressed as mean ± SD. Student’s 
t test (unpaired, 2 tailed) was used for comparison between experimental 
groups. A P value of less than 0.05 was considered significant.
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